According to the "Announcement of the First List 'Specialization, Refinement, Specialty, Innovation' Small and Medium Enterprises in Zhejiang Province in 2022 by Economic and Information Technology Department of Zhejiang Province" recently released by Economic and Information Technology Department of Zhejiang Province, Hangzhou DALTON BioSciences, Ltd. (DALTONbio) was successfully selected as one of the "Specialization, Refinement, Specialty, Innovation" Small and Medium Enterprises in Zhejiang Province in 2022, based on its outstanding technological innovation and market performance.

Small and Medium Enterprises with the characteristics of "Specialization, Refinement, Specialty, Innovation", is an important part of the gradient cultivation system of high-quality enterprises in Zhejiang Province. Enterprises are at leading level in technology, market, quality, efficiency and other aspects of the domestic industry with advanced nature and demonstration, they are important force to promote high-quality economic and social development.

"Specialization, Refinement, Specialty, Innovation" of DALTONbio

Founded in 2010 in Hangzhou Zhejiang Province, DALTONbio is a high-tech enterprise focusing on the fields of obstetrics, gynecology, oncology, infectious diseases, integrating R&D, production and sales. Continuing to carry out product R&D and be committed to developing internationally leading biomedical application technologies, DALTONbio owns fully independent intellectual property rights of GRT technology and other international cutting-edge molecular immune as well as other diagnostic technologies. It has developed a series of molecular genetic diagnostic reagents with an advanced technology platform, a number of invention patents and won several national science and technology awards.

The award of "Specialization, Refinement, Specialty, Innovation" Small and Medium Enterprises in Zhejiang Province is not only a recognition and affirmation of DALTONbio's focusing on women's health field, deep commitment to technology R&D, innovation capability cultivation, and continuous improvement of its competitiveness, but also a milestone of DALTONbio's steady progress on the road of "capability cultivation, and continuous improvement of its competitiveness, but also a miles". In the future, DALTONbio will continue to cultivate the field of obstetrics, gynecology and female oncology, increase the investment in research and development, further enhance the independent innovation ability, and lead the industry development.